Etanercept

Evidence Level: L5

Predicted Indications: 3

Etanercept

Pharmacist Assessment Report

Etanercept: Hypermobility of coccyx

One-Sentence Summary

Etanercept is a TNF-alpha blocking fusion protein, originally used for inflammatory arthritis conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Evidence is weak, and the benefit-risk balance is unresolved.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Hypermobility of coccyx
TxGNN Prediction Score	0.9963
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (5 of 5) – CDSCO approval status is not included in this data
Number of Listed Products	5 (valid: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, etanercept is a soluble TNF receptor fusion protein that neutralizes TNF-alpha, and its efficacy in rheumatoid arthritis is established. Mechanistically, it may be applicable to extra-articular vascular inflammation in rheumatoid disease.

Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis, so the link to the original indication is close. However, the literature also contains reports of etanercept-associated cutaneous vasculitis, leukocytoclastic vasculitis and nephropathy. This suggests TNF blockade can paradoxically induce vasculitis in some patients. The systematic review of biologics in rheumatoid vasculitis and the review of TNF blockade in ANCA-associated vasculitis are indirect evidence, and the benefit-risk balance remains unresolved.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07138898	Phase 2	Recruiting	80	Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty; does not test etanercept for rheumatoid vasculitis, so it provides no efficacy evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33058033	2021	Systematic Review	Clin Rheumatol	Systematic review of biological drugs in rheumatoid vasculitis
28391344	2017	Review	Nephrol Dial Transplant	Role of TNFα blockade in ANCA-associated vasculitis and glomerulonephritis (indirect)
16624928	2006	Review	J Am Soc Nephrol	Role of TNF-alpha in ANCA-associated vasculitis, drawing on other chronic inflammatory diseases
28123776	2017	Cohort	RMD Open	Drug-specific risk of lupus-like and vasculitis-like events in RA patients treated with TNF inhibitors (BSRBR-RA)
31632872	2019	Case report	Cureus	Etanercept-associated nephropathy
10955351	2000	Case report	J Rheumatol	Leukocytoclastic vasculitis due to etanercept
12209493	2002	Case report	Arthritis Rheum	Accelerated nodulosis and vasculitis after etanercept for RA
25544845	2014	Case report	Case Rep Med	Large vessel vasculitis in an RA patient on anti-TNF therapy
15853915	2005	Review	Scand J Immunol	Immunology of cutaneous vasculitis associated with etanercept and infliximab
19648728	2009	Case report	Dermatology	Disseminated herpes zoster mimicking rheumatoid vasculitis in a patient on etanercept

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
78131	Enbrol 25mg Injection	Vial of 1 ml injection	Not stated
72878	Etacept PFS Injection	Vial of 1 ml injection	Not stated
72742	Etacept 25mg Injection	Vial of 3 ml injection	Not stated
107850	Intacept 50mg Injection	Vial of 1 ml injection	Not stated
108176	Intacept 25 Solution for Injection	Vial of 0.5 ml solution for injection	Not stated

Safety Considerations

Drug Interactions: 352 interactions were recorded. Major interactions include corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisone, prednisolone), deferiprone, and radiopharmaceuticals/radioimmunotherapies (iobenguane I-131, ibritumomab tiuxetan, tositumomab). Moderate interactions include metronidazole, tinidazole, rosuvastatin and simvastatin.
Other considerations from the literature: Reports of etanercept-associated vasculitis and nephropathy are directly relevant to this indication, as is the risk of infections such as herpes zoster.

Please refer to the package insert for further safety information, including warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The benefit-risk balance is unresolved.

To proceed, the following is needed:

Direct clinical evidence (controlled or well-designed observational studies) of etanercept in rheumatoid vasculitis
Analysis of paradoxical vasculitis risk with TNF inhibitors in this population
Mechanism of action data and package insert warnings and contraindications

Other Predicted Indications (Brief Notes)

Inflammatory spondylopathy (L1, Proceed with Guardrails): Overlaps with already-labeled ankylosing spondylitis and axial spondyloarthritis, with Phase 3 placebo-controlled and long-term extension trials. This is largely a re-mapping of an existing indication rather than true repurposing. Guardrails: dose optimization, uveitis risk, standard TNF-inhibitor safety monitoring.
Polyarticular juvenile rheumatoid arthritis (L1, Proceed with Guardrails): A labeled juvenile idiopathic arthritis use supported by Phase 3 trials and a meta-analysis versus adalimumab. Guardrails: paediatric dosing, infection screening, tapering strategy.
Vertebral disease (L4, Research Question): A non-specific category. Evidence is indirect and covers inflammatory subtypes already included under inflammatory spondylopathy.
Hypermobility of coccyx and Kummell disease (L5, Hold): No trials or literature, and no credible TNF-related mechanism in the data.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.